Skip to main content
OpenTrials
Completed

NCT Number: NCT02191254

Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency

Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical Class 3, or 4a)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female
  • 18 years of age or older
  • CVI, Clinical Class 3 (oedema) or 4a (mild skin changes ascribed to venous disease, e.g. pigmentation), according to the CEAP classification
  • Willing and able to give written informed consent prior to participation in the study

Exclusion criteria

Concomitant diseases:

  • Decompensated cardiac insufficiency
  • Oedema not due to venous disease of the legs (e.g., latent cardiac insufficiency, renal insufficiency, lymphoedema, etc)
  • Peripheral arterial disease (ankle/arm pressure index < 0.9)
  • Current acute phlebitis or thrombosis
  • Renal insufficiency (serum creatinine > 1.5 mg/dl)
  • Liver disease (SGPT > 3x upper limit of normal)
  • Other diseases: hyper- or hypocalcaemia, malignancies
  • Anamnestic indications of diabetic microangiopathy or polyneuropathy
  • Drug and/or alcohol abuse
  • Severe climacteric complaints: changes in, or initiation with post-menopausal hormone replacement therapy within the last 3 months
  • Immobility
  • Avalvulia
  • Klippel-Trénaunay-Weber-Syndrome (Naevus varicosis osteohypertrophicus, Haemangiectasia hypertrophicans)
  • State after pulmonary embolism
  • Recognised hypersensitivity to the trial drug ingredients
  • Current florid venous ulcus
  • Clinical indication for a necessary, specific phlebologic acute treatment, e.g. compression treatment, phlebectomy, etc.

Previous treatments:

  • Patients who are on compression therapy and/or are wearing support stockings and who optimally benefit from these measures
  • Treatment with venous drugs within the last 2 weeks prior to the intake of study medication
  • Changes in or unstable response to treatment with theophylline, diuretics, cardiac glycosides, ACE inhibitors, calcium antagonists, or laxatives within the last 2 weeks prior to the intake of study medication

Concomitant treatment/non-drug therapy exclusion criteria:

  • Other venous drugs apart from the trial medication
  • Venous surgery or sclerotherapy within the last 12 month at the leg used for volumetry
  • Extensive use of laxatives
  • Major surgery requiring full anaesthesia

Other exclusion criteria:

  • Previously studied under this protocol
  • Participation in another clinical trial within the previous 90 days or during the present study
  • Patient is investigator, co-investigator, or study nurse in this study
  • Pregnant or nursing women or inadequate birth control methods (this applies to females of childbearing potential only)
  • Patients considered as mentally ill as well as unable to work or with limited working ability, or unable (or only partially able) to follow the spoken or written explanations concerning the trial
  • Patients in a bad general health state according to the investigator's judgement

Treatment and study plan

Antistax®

Drug

Placebo

Drug

Primary outcomes

  1. Change from baseline in limb volume determination

    Time frame: Baseline, day 84

    water displacement method

Secondary outcomes

  1. Changes in limb volume determination

    Time frame: Baseline, day 21 and day 42

    water displacement method

  2. Changes in the calf circumference

    Time frame: Baseline, at day 21, 42 and 84

    in centimeters

  3. Changes in the ankle circumference

    Time frame: Baseline, at day 21, 42, and 84

    in centimeters

  4. Changes in the subjective symptoms of CVI measured by Visual Analogue Scales (VAS)

    Time frame: Baseline, at day 21, 42, and 84

  5. Global assessment of efficacy by the patient on a 4-point verbal rating scale (VRS)

    Time frame: day 84

  6. Global assessment of efficacy by the investigator on a 4-point VRS

    Time frame: day 84

  7. Global assessment of tolerability by the patient on a 4-point VRS

    Time frame: day 84

  8. Global assessment of tolerability by the investigator on a 4-point VRS

    Time frame: Day 84

  9. Number of patients with adverse events

    Time frame: up to 12 weeks

  10. Number of patients with clinically significant changes in laboratory values

    Time frame: Baseline, week 12

  11. Number of patients with clinically significant changes in vital signs (Blood Pressure (BP), Pulse Rate (PR))

    Time frame: Baseline, up to 12 weeks

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency

Important dates

Study start
2004
Primary completion
2004
First posted
Jul 16, 2014
Registry last updated
Jul 16, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.